1 / 1

Methods

COBRA*: 1-Year Retention and Outcome of Methadone and Buprenorphine Maintenance in Different Care Settings in Germany Apelt SM, Bühringer G, Siegert J, Soyka M & Wittchen H-U Institute of Clinical Psychology and Psychotherapy, Technische Universität Dresden. 2,694 patients (223 doctors).

Rita
Télécharger la présentation

Methods

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. COBRA*: 1-Year Retention and Outcome of Methadone and Buprenorphine Maintenance in Different Care Settings in Germany Apelt SM, Bühringer G, Siegert J, Soyka M & Wittchen H-U Institute of Clinical Psychology and Psychotherapy, Technische Universität Dresden 2,694 patients (223 doctors) baseline 8 doctors withdrew participation (N = 66 patients) Prestudy 405 patients discontinued therapy, reasons were: 1 – death n = 13 2 – disciplinary reasons n = 58 3 – treatment success (clean) n = 55 4 – change to drug-free therapy n = 86 5 – side effects n = 0 6 – change of residence n = 135 7 – other/unknown n = 58 OR 0.41** 1st short assessment (6-month-fu) 2,223 patients still in treatment (215 doctors) Representative sample of substitution physicians in Germany(N=3006) Random sample Participation at prestudy (Jun-Sep/2003): N=379 physicians OR 0.51*** OR 0.58*** Prestudy Questionnaire Maintenance Staff Questionnaire 9 doctors withdrew participation (N = 47 patients) 169 patients discontinued therapy, reasons were: 1 – death n = 5 2 – disciplinary reasons n = 29 3 – treatment success (clean) n = 15 4 – change to drug-free therapy n = 37 5 – side effects n = 0 6 – change of residence n = 52 7 – other/unknown n = 31 OR 0.73** 2nd short assessment (9-month-fu) 2,007 patients still in treatment (206 doctors) Main Study Target week assessment (Feb-Mar/2004) Small setting (<10 p/d) Medium setting (10-40 p/d) Large setting (>40 p/d) 12 doctors withdrew participation (N = 120 patients) 256 patients discontinued therapy, reasons were: 1 – death n = 10 2 – disciplinary reasons n = 32 3 – treatment success (clean) n = 30 4 – change to drug-free therapy n = 51 5 – side effects n = 0 6 – change of residence n = 67 7 – other/unknown n = 66 Patients Questionnaire Urine Drug Screening Doctors Questionnaire 12-month follow-up 1,631 patients still in treatment (194* doctors) Follow-Up 6- and 9-month Follow-up Monitoring with Drop-out Documentation 830 patients with complete drop-out documentation! Reasons for drop-out were: 1 – death n = 28 2 – disciplinary reasons n = 119 3 – treatment success (clean) n = 100 4 – change to drug-free therapy n = 174 5 – side effects n = 0 6 – change of residence n = 254 7 – other/unknown n = 155 documentation available of 2,461 patients Response Rate = 91,35% Target week assessment of 12-month Follow-up summary Patients Questionnaire Urine Drug Screening Doctors Questionnaire * Cost-Benefit and Risk Appraisal of Substitution Treatment Background Extract of Objectives Results • Buprenorphine and methadone are two established substitution drugs licensed in many countries for the maintenance treatment of opioid dependence. • Little ist known about how these two treatments work under routine care conditions... • ...and particular in different provider formats, such as small, primary care based and large, specialized substitution centres. 12-MONTH RETENTION To describe over a period of 12 months: • Differences in retention rates... • Differences in concomitant drug use... • Differences in therapy outcome... ...in a nationally representative sample of N=223 substitution • physicians and a total of N=2,694 consecutive patients in • substitution treatment. Settings were divided into small, primary • care based settings (<10 patients per day) and large, specialized substitution centres (>40 patients per day). Retention rate (%) Methods weeks after baseline ATTAINMENT OF TREATMENT TARGETS % Conclusion References & Publications • The study confirms an overall effectiveness of agonist maintenance treatments in routine care. • Small-scale, primary care based settings perform as well or better as large-scale substitution centres... • ...suggesting that these primary care based settings might be a promising alternative to improve access to maintenance therapy in underserved areas. • Further analyses of possible patient‘ diffences between settings are necessary. CONCOMITANT DRUG USE Wittchen, H.-U., Apelt, S. M., Soyka, M., Bühringer, G. et al. (2005). Buprenorphine and methadone in the treatment of opioid dependence: methods and design of the COBRA study. International Journal of Methods in Psychiatric Research, 14(1), 14-28 Wittchen, H.-U. (2005). Buprenorphine and Methadone Treatments in Routine Care: Findings from the 12-month COBRA Cohort Study in Germany. Conference Abstract Book, "Safer Options in the Treatment of Opioid Dependence", Day 3, S. 16 Apelt, Sabine M. (2005). Correlates of High-Risk Behavior Among Methadone and Buprenorphine Patients with HIV (COBRA). NIDA 2005 International Forum Abstracts, Page 5 of 52 Apelt, S.M., Siegert, J. & Wittchen, H.-U. (2005). Substitution in Routine Care: Retention Rates after 9 Months of Follow-up (COBRA). WPA-World Congress 2005 Abstract Book, Page 607 Wittchen, H.-U., Apelt, S.M., Mühlig, S. (2005). Die Versorgungslage der Substitutionstherapie. Buchbeitrag in Gerlach, R. & Stöver, H. (Hrsg.) Vom Tabu zur Normalität: 20 Jahre Substitution in Deutschland - Zwischenbilanz und Aufgaben für die Zukunft. Wittchen, H.-U., Apelt, S. M., Christl, B., Hagenau, K. A., Groß, A., Klotsche, J. & Soyka, M. (2004). Die Versorgungspraxis der Substitutionstherapie Opiatabhängiger (COBRA). Suchtmed 6 (1) 80-87 *without methadone-patients ASAT BMBF -SuchtforschungsverbundSachsen – Bayern Allocating Substance Abuse Treatments to Patient Heterogeneity This work has been prepared in the context of the project F8 “Allocation in substitution treatments – COBRA (PI) within the Addiction Research Network ASAT (Allocating Substance Abuse Treatments to Patient Heterogeneity).Contact information: e-mail: asatkoordination@mpipsykl.mpg.de (www.asat-verbund.de). ASAT is sponsored by a federal grant of the Federal Ministry of Education and Research (01 EB 0440 - 0441, 01 EB 0142). First phases of this project have been funded in addition by an unrestricted educational grant of essex pharma GmbH, Munich, Germany . COBRA contact information: COBRA@psychologie.tu-dresden.de

More Related